St. Jude to Open Grad School for Biomedical Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ST. JUDE CHILDREN’S RESEARCH HOSPITAL has received a unanimous vote of approval from the Tennessee Higher Education Commission for the opening of a new graduate school of biomedical sciences.

Stephen White, a faculty member in the St. Jude Department of Structural Biology, will serve as dean of the graduate school. The school will be located in the Marlo Thomas Center for Global Education and Collaboration, and will welcome the inaugural class in fall 2017.

“The graduate school will play an important role in our research efforts to advance cures for pediatric catastrophic diseases,” said James Downing, St. Jude president and CEO, “Talented graduate students are a creative and energetic force that will contribute to the kind of innovation required for progress against cancer and other life-threatening diseases. These students will ask the unexpected questions, challenge fundamental assumptions and will help tackle the most difficult scientific problems.”

Students will also interact with the neighboring University of Tennessee Health Science Center and Le Bonheur Children’s Hospital.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login